A detailed history of Clifford Swan Investment Counsel LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Clifford Swan Investment Counsel LLC holds 457,116 shares of BMY stock, worth $26.5 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares
457,116
Previous 405,579 12.71%
Holding current value
$26.5 Million
Previous $16.8 Million 40.44%
% of portfolio
0.85%
Previous 0.63%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $2.04 Million - $2.67 Million
51,537 Added 12.71%
457,116 $23.7 Million
Q2 2024

Aug 06, 2024

SELL
$40.25 - $52.99 $625,847 - $823,941
-15,549 Reduced 3.69%
405,579 $16.8 Million
Q1 2024

Apr 16, 2024

SELL
$47.98 - $54.4 $129,354 - $146,662
-2,696 Reduced 0.64%
421,128 $22.8 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $723,467 - $863,295
-14,923 Reduced 3.4%
423,824 $21.7 Million
Q3 2023

Nov 09, 2023

SELL
$57.89 - $64.73 $130,310 - $145,707
-2,251 Reduced 0.51%
438,747 $25.5 Million
Q2 2023

Aug 03, 2023

SELL
$63.71 - $70.74 $246,493 - $273,693
-3,869 Reduced 0.87%
440,998 $28.2 Million
Q1 2023

May 05, 2023

SELL
$65.71 - $74.53 $171,831 - $194,895
-2,615 Reduced 0.58%
444,867 $30.8 Million
Q4 2022

Feb 02, 2023

SELL
$68.48 - $81.09 $1.52 Million - $1.8 Million
-22,166 Reduced 4.72%
447,482 $32.2 Million
Q3 2022

Nov 04, 2022

SELL
$0.13 - $76.84 $3,285 - $1.94 Million
-25,275 Reduced 5.11%
469,648 $33.4 Million
Q2 2022

Aug 04, 2022

SELL
$72.62 - $79.98 $749,728 - $825,713
-10,324 Reduced 2.04%
494,923 $38.1 Million
Q1 2022

May 03, 2022

SELL
$61.48 - $73.72 $1.24 Million - $1.49 Million
-20,242 Reduced 3.85%
505,247 $36.9 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $20,164 - $23,507
376 Added 0.07%
525,489 $32.8 Million
Q3 2021

Nov 02, 2021

BUY
$59.17 - $69.31 $238,455 - $279,319
4,030 Added 0.77%
525,113 $31.1 Million
Q2 2021

Aug 05, 2021

BUY
$61.91 - $67.42 $742 - $809
12 Added 0.0%
521,083 $35.7 Million
Q1 2021

May 07, 2021

BUY
$59.34 - $66.74 $50,676 - $56,995
854 Added 0.16%
521,071 $32.9 Million
Q4 2020

Feb 11, 2021

SELL
$57.74 - $65.43 $810,842 - $918,833
-14,043 Reduced 2.63%
520,217 $32.3 Million
Q3 2020

Oct 30, 2020

SELL
$57.43 - $63.64 $6,776 - $7,509
-118 Reduced 0.02%
534,260 $32.2 Million
Q2 2020

Aug 06, 2020

SELL
$54.82 - $64.09 $260,230 - $304,235
-4,747 Reduced 0.88%
534,378 $31.4 Million
Q1 2020

Apr 09, 2020

SELL
$46.4 - $67.43 $76,792 - $111,596
-1,655 Reduced 0.31%
539,125 $30.1 Million
Q4 2019

Jan 30, 2020

BUY
$49.21 - $64.19 $150,582 - $196,421
3,060 Added 0.57%
540,780 $34.7 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $576,282 - $683,266
13,474 Added 2.57%
537,720 $27.3 Million
Q2 2019

Aug 13, 2019

BUY
$44.62 - $49.34 $1.75 Million - $1.93 Million
39,198 Added 8.08%
524,246 $23.8 Million
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $1.3 Million - $1.55 Million
28,855 Added 6.33%
485,048 $23.1 Million
Q4 2018

Feb 13, 2019

BUY
$48.76 - $63.23 $23,599 - $30,603
484 Added 0.11%
456,193 $23.7 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $509,514 - $574,692
9,232 Added 2.07%
455,709 $28.3 Million
Q2 2018

Aug 13, 2018

BUY
$50.53 - $62.98 $360,430 - $449,236
7,133 Added 1.62%
446,477 $24.7 Million
Q1 2018

May 09, 2018

SELL
$59.92 - $68.98 $372,462 - $428,779
-6,216 Reduced 1.4%
439,344 $27.8 Million
Q4 2017

Feb 09, 2018

BUY
$59.94 - $65.35 $5.67 Million - $6.18 Million
94,541 Added 26.93%
445,560 $27.3 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $792,274 - $914,350
14,345 Added 4.26%
351,019 $22.4 Million
Q2 2017

Aug 11, 2017

BUY
N/A
336,674
336,674 $18.8 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Clifford Swan Investment Counsel LLC Portfolio

Follow Clifford Swan Investment Counsel LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clifford Swan Investment Counsel LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clifford Swan Investment Counsel LLC with notifications on news.